SRPT Stock Analysis: Sarepta Therapeutics | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 1.986m USD | 12M Return: -5.5% | US8036071004 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 56.4M
Qual. Beats: 0
Rev. Trend: 85.7%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Sarepta Therapeutics (NASDAQ: SRPT) is a Cambridge, Massachusetts-based biopharmaceutical company incorporated in 1980 that develops RNA-targeted therapeutics, siRNA candidates, and gene therapies for rare diseases, with a heavy focus on Duchenne muscular dystrophy (DMD). It has four approved products on the market: EXONDYS 51, VYONDYS 53, and AMONDYS 45 (each an exon-skipping therapy tailored to patients with specific mutations in the dystrophin gene amenable to skipping exon 51, 53, or 45, respectively), and ELEVIDYS, an AAV-based gene therapy for DMD.
The pipeline includes SRP-9003 for LGMD2E, SRP-1001 (an RNAi therapy targeting DUX4), and SRP-1003 (for DMPK gene knockdown), both in Phase 1/2a clinical trials. Sarepta operates in the rare/orphan disease segment of biotech, relying on a mix of FDA-approved therapies and early-stage R&D supported by collaborations and licensing deals with partners such as F. Hoffmann-La Roche, Arrowhead Pharmaceuticals, the University of Western Australia, Nationwide Childrens Hospital, Hansa Biopharma, and Duke University.
Context on the business model: as a commercial-stage rare-disease company, Sarepta typically benefits from regulatory protections such as orphan drug exclusivity, which grants marketing exclusivity for therapies targeting conditions affecting fewer than 200,000 U.S. patients. Its portfolio spans multiple antisense and gene-therapy platforms, with revenue concentration largely in a single indication (DMD).
- ELEVIDYS gene therapy revenue growth drives quarterly results
- FDA label restrictions on ELEVIDYS follow reported safety events
- PMO franchise revenue declines as gene therapy competition intensifies
| Net Income: -136.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.04 > 0.02 and ΔFCF/TA 8.21 > 1.0 |
| NWC/Revenue: 87.16% < 20% (prev 70.00%; Δ 17.17% < -1%) |
| CFO/TA -0.03 > 3% & CFO -91.7m > Net Income -136.7m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 4.42 > 1.5 & < 3 |
| Outstanding Shares: last quarter (105.4m) vs 12m ago -1.12% < -2% |
| Gross Margin: 58.56% > 18% (prev 79.28%; Δ -20.73% > 0.5%) |
| Asset Turnover: 57.49% > 50% (prev 67.44%; Δ -9.95% > 0%) |
| Interest Coverage Ratio: -1.02 > 6 (EBIT TTM -59.3m / Interest Expense TTM 58.4m) |
| A: 0.54 (Total Current Assets 2.22b - Total Current Liabilities 502.9m) / Total Assets 3.19b |
| B: -1.43 (Retained Earnings -4.55b / Total Assets 3.19b) |
| C: -0.02 (EBIT TTM -59.3m / Avg Total Assets 3.43b) |
| D: 0.92 (Book Value of Equity 1.53b / Total Liabilities 1.66b) |
| Altman-Z'' = -0.26 = B |
| DSRI: 1.00 (Receivables 482.6m/609.6m, Revenue 1.97b/2.48b) |
| GMI: 1.35 (GM 79.28% / 58.56%) |
| AQI: 1.18 (AQ_t 0.16 / AQ_t-1 0.14) |
| SGI: 0.80 (Revenue 1.97b / 2.48b) |
| TATA: -0.01 (NI -136.7m - CFO -91.7m) / TA 3.19b) |
| Beneish M = -2.75 (Cap -4..+1) = A |
As of October 01, 2026, the stock is trading at USD 18.22 with a total of 1,995,000 shares traded. Over the past week, the price has changed by -3.85%, over one month by -13.36%, over three months by +1.39% and over the past year by -5.45%.
Current recommended Stop Loss: 17.00 (which is 6.7% or 1 ATR below the current price).
Sarepta Therapeutics has received a consensus analysts rating of 4.38. Therefore, it is recommended to buy SRPT.
- StrongBuy: 14
- Buy: 8
- Hold: 4
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 21.9 | 20% |
P/E Forward = 19.1571
P/S = 1.0058
P/B = 1.3101
P/EG = 159.25
Revenue TTM = 1.97b USD
EBIT TTM = -59.3m USD
EBITDA TTM = -14.6m USD
Long Term Debt = 847.6m USD (from longTermDebt, last quarter)
Short Term Debt = 11.4m USD (from shortTermDebt, last fiscal year)
Debt = 1.24b USD (from shortLongTermDebtTotal, last quarter) + Leases 198.2m
Net Debt = 455.6m USD (calculated: Debt 1.24b - CCE 788.5m)
Enterprise Value = 2.44b USD (1.99b + Debt 1.24b - CCE 788.5m)
Interest Coverage Ratio = -1.02 (Ebit TTM -59.3m / Interest Expense TTM 58.4m)
EV/FCF = -18.57x (Enterprise Value 2.44b / FCF TTM -131.5m)
FCF Yield = -5.38% (FCF TTM -131.5m / Enterprise Value 2.44b)
FCF Margin = -6.66% (FCF TTM -131.5m / Revenue TTM 1.97b)
Net Margin = -6.93% (Net Income TTM -136.7m / Revenue TTM 1.97b)
Gross Margin = 58.56% ((Revenue TTM 1.97b - Cost of Revenue TTM 818.2m) / Revenue TTM)
Gross Margin QoQ = 62.77% (prev 83.67%)
Tobins Q-Ratio = 0.77 (Enterprise Value 2.44b / Total Assets 3.19b)
Interest Expense / Debt = 4.69% (Interest Expense 58.4m / Debt 1.24b)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -46.8m (EBIT -59.3m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 4.42 (Total Current Assets 2.22b / Total Current Liabilities 502.9m)
Debt / Equity = 0.81 (Debt 1.24b / totalStockholderEquity, last quarter 1.53b)
Debt / EBITDA = -31.24 (negative EBITDA) (Net Debt 455.6m / EBITDA -14.6m)
Debt / FCF = -3.47 (negative FCF - burning cash) (Net Debt 455.6m / FCF TTM -131.5m)
Total Stockholder Equity = 1.37b (last 4 quarters mean from totalStockholderEquity)
RoA = -3.98% (Net Income -136.7m / Total Assets 3.19b)
RoE = -9.96% (Net Income TTM -136.7m / Total Stockholder Equity 1.37b)
RoCE = -2.67% (EBIT -59.3m / Capital Employed (Equity 1.37b + L.T.Debt 847.6m))
RoIC = -1.80% (negative operating profit) (NOPAT -46.8m / Invested Capital 2.60b)
WACC = 7.43% (E(1.99b)/V(3.23b) * Re(9.77%) + D(1.24b)/V(3.23b) * Rd(4.69%) * (1-Tc(0.21)))
Discount Rate = 9.77% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 56.65 | Cagr: 2.78%
[DCF] Fair Price = unknown (Cash Flow -131.5m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.05 | # QB: 0
Revenue Correlation: 85.71 | Revenue CAGR: 29.28% | SUE: 0.46 | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.42 | Chg30d=-13.23% | Revisions=-8% | Analysts=10
EPS current Year (2026-12-31): EPS=4.44 | Chg30d=+0.98% | Revisions=-21% | GrowthEPS=+187.8% | GrowthRev=-16.5%
EPS next Year (2027-12-31): EPS=2.63 | Chg30d=+2.34% | Revisions=+7% | GrowthEPS=-40.7% | GrowthRev=-24.8%
[Analyst] Revisions Ratio: -9% (up=14, down=17)